

ASX: CVB

7 January 2026

CurveBeam AI Notified of China ODI Approval for Strategic Investment

- **China ODI (Outbound Direct Investment) refers to the formal Chinese regulatory approval process required for Chinese entities to make offshore strategic investments. Approval confirms that the investment has been reviewed and authorised by the relevant Chinese authorities, and that funds are permitted to be remitted offshore in accordance with foreign exchange and capital controls**
- **Funds from the first tranche of A\$4m expected in January 2026 – upon receipt of funds the company will notify the market**
- **The investment forms part of the recently announced long-term joint venture and expansion into China**
- **Shares will be issued as part of the A\$4m investment at \$0.405 per share, a significant premium to CurveBeam AI's last traded price of around \$0.075 per share**
- **A further \$6m available for investment (also at \$0.405 per share) upon achievement of specific commercial and regulatory milestones**
- **The 10-year commercialisation agreement covers sales, marketing, distribution, manufacturing, regulatory support & intellectual property in China and associated regions**
- **Supported by WEGO Orthopaedics, a major Chinese supplier of orthopaedic implants and surgical robotics**

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB, "CurveBeam AI" or the "Company"), a fully integrated developer and manufacturer of point-of-care specialised medical imaging (CT) equipment, supported by a range of AI enabled SaaS-based clinical assessment solutions, is pleased to announce that it has been advised of the ODI approval and sign off for the strategic equity investment from Shandong WeiYing Intelligent Medical Technology Co., Ltd, a subsidiary of Shandong Weigao Orthopaedic Materials Co., Ltd (WEGO Orthopaedics), pursuant to the previously announced binding agreements for the commercialisation of CurveBeam AI's weight-bearing CT (WBCT) and proprietary AI solutions in greater China.

The approval covers the A\$4.0 million investment which represents the first tranche of a strategic investment of up to A\$10.0 million, with the remaining A\$6.0 million payable upon achievement of specified commercial and regulatory milestones. Shares will be issued at A\$0.405 per share, in accordance with the agreement.

As announced 30 October 2025, the investment forms part of a broader 10-year exclusive commercialisation arrangement covering sales, marketing, distribution, manufacturing, regulatory support and intellectual property for CurveBeam AI's WBCT and AI technologies in China, Hong Kong, Macau and Taiwan. The agreements are supported by WEGO Orthopaedics, one of China's leading orthopaedic medical device companies.

CurveBeam AI Chief Executive Officer, Greg Brown, said: "Being advised of this approval and formal sign-off under the China ODI framework is an important milestone for CurveBeam AI and reflects the continued broader support of this strategic investment for our commercial partner,

WEGO Orthopaedics and its affiliates. The China ODI approval process is administered by regulatory authorities and as previously disclosed, the timing of such approvals is outside our control. The Company is pleased to confirm that the approval process has now been completed. Funds associated with the initial A\$4.0 million tranche are expected to be received during January 2026. Proceeds are intended to be applied toward regulatory, manufacturing and commercial activities in Greater China, in line with the Company's stated strategy. Subject to the achievement of agreed milestones, additional investment tranches of up to A\$6.0 million in aggregate may be received in due course."

The funds, once received, strengthens CurveBeam AI's financial position and supports execution of its global growth strategy, providing a pathway to target long-term revenue growth and royalties from a major international market.

This announcement has been authorised for release by the Board of CurveBeam AI Limited.

For further information:

Greg Brown
CEO & MD
CurveBeam AI Limited
greg.brown@curvebeamai.com

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

About Shandong WeiYing Intelligent Medical Technology Co., Ltd.

Shandong Weiying Intelligent Medical Technology Co., Ltd. is a newly established Chinese medical technology company located in the Torch Hi-Tech Industrial Development Zone, Weihai, Shandong Province. The company is a joint venture between Shandong Weigao Haixing Medical Device Co., Ltd and other partners.

About Shandong Weigao Haixing Medical Device Co., Ltd

Shandong Weigao Haixing Medical Device Co., Ltd is a subsidiary of Shandong Weigao Orthopaedic Materials Co., Ltd. ("WEGO Orthopaedics"). WEGO Orthopaedics is a leading Chinese medical device company specialising in the research, development, manufacture, and sale of orthopaedic medical devices. Its core product portfolio includes orthopaedic implant systems and surgical instruments used in trauma, spine, joint replacement, and sports medicine procedures.

WEGO Orthopaedics is recognised as one of China's most comprehensive and competitive orthopaedic implant manufacturers, holding the largest domestic market share among orthopaedic device suppliers. The company has established a fully integrated R&D and manufacturing system, equipped with internationally advanced facilities and modern project management capabilities. Through continuous innovation and product iteration, WEGO Orthopaedics has developed a broad and diversified product line that meets the full spectrum of clinical needs in orthopaedic surgery. The company is a subsidiary of the WEGO Group, one of China's largest and most diversified healthcare conglomerates.